---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-116443"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2025-05-09T23:59:59+00:00"
generated_at: "2026-05-22T02:00:20.422522+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kymera Q1 net loss $65.6M, cash $775M; unveils oral IRF5 degrader KT-579; STAT6 data June

## Summary
- Net loss $65.6M (Q1 2025) vs $48.6M (Q1 2024); collab revenue $22.1M incl $20M Sanofi milestone.
- Cash $775M as of Mar 31, 2025; runway extended into H1 2028.
- KT-621 (STAT6) Ph1 SAD/MAD healthy volunteer data due June 2025; BroADen Ph1b in AD started, data 4Q25.
- New oral IRF5 degrader KT-579 unveiled; IND-enabling ongoing, Phase 1 expected early 2026.
- Strategic decision to not advance KT-295 (TYK2) into clinic; focus on STAT6 and IRF5.

## SEC filing metadata
- accession: 0001193125-25-116443
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2025-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312525116443/0001193125-25-116443-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312525116443/d27625d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-116443
- JSON: https://secwatch.observer/filing/0001193125-25-116443.json
- Plain text: https://secwatch.observer/filing/0001193125-25-116443.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.